InMed Pharmaceuticals (INM) Current Leases (2020 - 2026)
InMed Pharmaceuticals' (INM) quarterly Current Leases came in at $389381.0 in Q1 2026, down 9.29% year-on-year from $429247.0 in Q1 2025, and down 4.59% quarter-over-quarter from $408122.0 in Q4 2025.
InMed Pharmaceuticals (INM) Current Leases (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Current Leases history runs 7 years deep, the most recent figure standing at $389381.0 for Q1 2026.
- On a quarterly basis, Current Leases fell 9.29% year-over-year to $389381.0 in Q1 2026; TTM through Mar 2026 was $389381.0, a 9.29% decrease from a year earlier, with the FY2025 full-year figure at $435507.0, up 37.04% from the prior year.
- Current Leases declined to $389381.0 in Q1 2026 per INM's latest filing, from $408122.0 in the prior quarter.
- Across five years, Current Leases topped out at $435507.0 in Q2 2025 and bottomed at $292998.0 in Q3 2023.
- The 5-year median for Current Leases is $404276.0 (2022), against an average of $392556.5.
- Across the five-year window, Current Leases surged 407.38% in 2022 and decreased 27.5% in 2023, its largest moves.
- Year by year, Current Leases stood at $414307.0 in 2022, then slipped by 12.1% to $364190.0 in 2023, then advanced by 15.25% to $419711.0 in 2024, then declined by 2.76% to $408122.0 in 2025, then declined by 4.59% to $389381.0 in 2026.
- Per Business Quant, the three latest INM Current Leases figures stand at $389381.0 (Q1 2026), $408122.0 (Q4 2025), and $424765.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | 389,381.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 389,381.00 |
| Dec 31, 2025 | 408,122.00 |
| Sep 30, 2025 | 424,765.00 |
| Jun 30, 2025 | 435,507.00 |
| Mar 31, 2025 | 429,247.00 |
| Dec 31, 2024 | 419,711.00 |
| Sep 30, 2024 | 424,260.00 |
| Jun 30, 2024 | 317,797.00 |
| Mar 31, 2024 | 345,545.00 |
| Dec 31, 2023 | 364,190.00 |
| Sep 30, 2023 | 292,998.00 |
| Jun 30, 2023 | 375,713.00 |
| Mar 31, 2023 | 423,574.00 |
| Dec 31, 2022 | 414,307.00 |
| Sep 30, 2022 | 404,163.00 |
| Jun 30, 2022 | 404,276.00 |
| Mar 31, 2022 | 399,904.00 |
| Dec 31, 2021 | 391,805.00 |
| Sep 30, 2021 | 82,232.00 |
| Jun 30, 2021 | 80,483.00 |